Skip to main content
NCBI home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 2005 Mar 10;64(9):1288–1293. doi: 10.1136/ard.2004.030908

A two year randomised controlled trial of intramuscular depot steroids in patients with established rheumatoid arthritis who have shown an incomplete response to disease modifying antirheumatic drugs

E Choy 1, G Kingsley 1, B Khoshaba 1, N Pipitone 1, D Scott 1, I the 1
PMCID: PMC1755652  PMID: 15760929

Abstract

Background: In rheumatoid arthritis (RA), intramuscular (IM) pulsed depomedrone expedites an immediate response to disease modifying antirheumatic drugs (DMARDs). Although IM depomedrone is also widely used to treat disease flares in patients treated with DMARDs, its effect on radiological progression has not been assessed.

Objective: To evaluate the benefits of 120 mg IM depomedrone versus placebo in patients with established RA whose disease was inadequately controlled by existing DMARDs.

Methods: In a 2 year prospective randomised controlled trial patients were assessed using the ILAR/WHO core dataset, disease activity score (DAS28), x ray examination of hands and feet scored by Larsen's method, and bone densitometry.

Results: 291 patients with RA were screened, 166 were eligible, and 91 consented and were randomised. Disease activity improved more rapidly in the steroid treated patients than with placebo, but after 6 months no difference remained. A small but significant reduction in erosive damage in the steroid group compared with placebo was also found. More adverse reactions occurred in the steroid treated group than in the placebo patients (55 v 42), especially those reactions traditionally related to steroids (16 v 2), including vertebral fracture, diabetes, and myocardial infarction. Hip bone density fell significantly in steroid treated but not placebo patients.

Conclusions: IM depomedrone improved disease activity in the short term and produced a small reduction in bone erosion at the cost of a significant increase in adverse events. Despite the initial benefit of IM depomedrone, when patients respond suboptimally to a DMARD they should not be given long term additional steroids but should be treated with alternative or additional DMARDs.

Full Text

The Full Text of this article is available as a PDF (91.2 KB).

Figure 1.

Figure 1

Open in a new tab

 Patients screened, entered, and withdrawn from the trial.

Figure 2.

Figure 2

Open in a new tab

 Changes in the DAS over 24 months. Mean values (SEM) shown for placebo and steroid treated groups.

Figure 3.

Figure 3

Open in a new tab

 Changes in Larsen score in placebo and steroid treated patients. (A) Mean (SEM) changes over 24 months; (B) percentage changes during the initial 12 months. Each circle represents an individual patient treated with placebo or steroids.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Boers M., Verhoeven A. C., Markusse H. M., van de Laar M. A., Westhovens R., van Denderen J. C., van Zeben D., Dijkmans B. A., Peeters A. J., Jacobs P. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet. 1997 Aug 2;350(9074):309–318. doi: 10.1016/S0140-6736(97)01300-7. [DOI] [PubMed] [Google Scholar]
  2. Capell H. A., Madhok R., Hunter J. A., Porter D., Morrison E., Larkin J., Thomson E. A., Hampson R., Poon F. W. Lack of radiological and clinical benefit over two years of low dose prednisolone for rheumatoid arthritis: results of a randomised controlled trial. Ann Rheum Dis. 2004 Jul;63(7):797–803. doi: 10.1136/ard.2003.014050. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Choy E. H., Kingsley G. H., Corkill M. M., Panayi G. S. Intramuscular methylprednisolone is superior to pulse oral methylprednisolone during the induction phase of chrysotherapy. Br J Rheumatol. 1993 Aug;32(8):734–739. doi: 10.1093/rheumatology/32.8.734. [DOI] [PubMed] [Google Scholar]
  4. Cohen Dana, Adachi Jonathan D. The treatment of glucocorticoid-induced osteoporosis. J Steroid Biochem Mol Biol. 2004 Apr;88(4-5):337–349. doi: 10.1016/j.jsbmb.2004.01.003. [DOI] [PubMed] [Google Scholar]
  5. Conn D. L. Resolved: Low-dose prednisone is indicated as a standard treatment in patients with rheumatoid arthritis. Arthritis Rheum. 2001 Oct;45(5):462–467. doi: 10.1002/1529-0131(200110)45:5<462::aid-art366>3.0.co;2-v. [DOI] [PubMed] [Google Scholar]
  6. Conn Doyt L., Lim S. Sam. New role for an old friend: prednisone is a disease-modifying agent in early rheumatoid arthritis. Curr Opin Rheumatol. 2003 May;15(3):193–196. doi: 10.1097/00002281-200305000-00004. [DOI] [PubMed] [Google Scholar]
  7. Corkill M. M., Kirkham B. W., Chikanza I. C., Gibson T., Panayi G. S. Intramuscular depot methylprednisolone induction of chrysotherapy in rheumatoid arthritis: a 24-week randomized controlled trial. Br J Rheumatol. 1990 Aug;29(4):274–279. doi: 10.1093/rheumatology/29.4.274. [DOI] [PubMed] [Google Scholar]
  8. Criswell L. A., Saag K. G., Sems K. M., Welch V., Shea B., Wells G., Suarez-Almazor M. E. Moderate-term, low-dose corticosteroids for rheumatoid arthritis. Cochrane Database Syst Rev. 2000;(2):CD001158–CD001158. doi: 10.1002/14651858.CD001158. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Criswell L. A., Such C. L., Yelin E. H. Differences in the use of second-line agents and prednisone for treatment of rheumatoid arthritis by rheumatologists and non-rheumatologists. J Rheumatol. 1997 Dec;24(12):2283–2290. [PubMed] [Google Scholar]
  10. Dieppe Paul, Bartlett Christopher, Davey Peter, Doyal Lesley, Ebrahim Shah. Balancing benefits and harms: the example of non-steroidal anti-inflammatory drugs. BMJ. 2004 Jul 3;329(7456):31–34. doi: 10.1136/bmj.329.7456.31. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Dolan A. L., Moniz C., Dasgupta B., Li F., Mackintosh C., Todd P., Corrigall V., Panayi G. S. Effects of inflammation and treatment on bone turnover and bone mass in polymyalgia rheumatica. Arthritis Rheum. 1997 Nov;40(11):2022–2029. doi: 10.1002/art.1780401115. [DOI] [PubMed] [Google Scholar]
  12. Gotzsche P. C., Johansen H. K. Short-term low-dose corticosteroids vs placebo and nonsteroidal antiinflammatory drugs in rheumatoid arthritis. Cochrane Database Syst Rev. 2003;(1):CD000189–CD000189. doi: 10.1002/14651858.CD000189. [DOI] [PubMed] [Google Scholar]
  13. Gotzsche P. C., Johansen H. K. Short-term low-dose corticosteroids vs placebo and nonsteroidal antiinflammatory drugs in rheumatoid arthritis. Cochrane Database Syst Rev. 2004;(3):CD000189–CD000189. doi: 10.1002/14651858.CD000189.pub2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Gough A., Sheeran T., Arthur V., Panayi G., Emery P. Adverse interaction between intramuscular methylprednisolone and sulphasalazine in patients with early rheumatoid arthritis. A pilot study. Scand J Rheumatol. 1994;23(1):46–48. doi: 10.3109/03009749409102135. [DOI] [PubMed] [Google Scholar]
  15. Hansen M., Podenphant J., Florescu A., Stoltenberg M., Borch A., Kluger E., Sørensen S. F., Hansen T. M. A randomised trial of differentiated prednisolone treatment in active rheumatoid arthritis. Clinical benefits and skeletal side effects. Ann Rheum Dis. 1999 Nov;58(11):713–718. doi: 10.1136/ard.58.11.713. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Heytman M., Ahern M. J., Smith M. D., Roberts-Thomson P. J. The longterm effect of pulsed corticosteroids on the efficacy and toxicity of chrysotherapy in rheumatoid arthritis. J Rheumatol. 1994 Mar;21(3):435–441. [PubMed] [Google Scholar]
  17. Hickling P., Jacoby R. K., Kirwan J. R. Joint destruction after glucocorticoids are withdrawn in early rheumatoid arthritis. Arthritis and Rheumatism Council Low Dose Glucocorticoid Study Group. Br J Rheumatol. 1998 Sep;37(9):930–936. doi: 10.1093/rheumatology/37.9.930. [DOI] [PubMed] [Google Scholar]
  18. Hickling P., Jacoby R. K., Kirwan J. R. Joint destruction after glucocorticoids are withdrawn in early rheumatoid arthritis. Arthritis and Rheumatism Council Low Dose Glucocorticoid Study Group. Br J Rheumatol. 1998 Sep;37(9):930–936. doi: 10.1093/rheumatology/37.9.930. [DOI] [PubMed] [Google Scholar]
  19. Hulsmans H. M., Jacobs J. W., van der Heijde D. M., van Albada-Kuipers G. A., Schenk Y., Bijlsma J. W. The course of radiologic damage during the first six years of rheumatoid arthritis. Arthritis Rheum. 2000 Sep;43(9):1927–1940. doi: 10.1002/1529-0131(200009)43:9<1927::AID-ANR3>3.0.CO;2-B. [DOI] [PubMed] [Google Scholar]
  20. Kirwan J. R. The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group. N Engl J Med. 1995 Jul 20;333(3):142–146. doi: 10.1056/NEJM199507203330302. [DOI] [PubMed] [Google Scholar]
  21. Landewé Robert B. M., Boers Maarten, Verhoeven Arco C., Westhovens Rene, van de Laar Mart A. F. J., Markusse Harry M., van Denderen J. Christiaan, Westedt Marie Louise, Peeters Andre J., Dijkmans Ben A. C. COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. Arthritis Rheum. 2002 Feb;46(2):347–356. doi: 10.1002/art.10083. [DOI] [PubMed] [Google Scholar]
  22. Landewé Robert B. M., Boers Maarten, Verhoeven Arco C., Westhovens Rene, van de Laar Mart A. F. J., Markusse Harry M., van Denderen J. Christiaan, Westedt Marie Louise, Peeters Andre J., Dijkmans Ben A. C. COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. Arthritis Rheum. 2002 Feb;46(2):347–356. doi: 10.1002/art.10083. [DOI] [PubMed] [Google Scholar]
  23. Lodder Mariette C., Haugeberg Glenn, Lems Willem F., Uhlig Till, Orstavik Ragnhild E., Kostense Piet J., Dijkmans Ben A. C., Kvien Tore K., Woolf Anthony D., Oslo-Truro-Amsterdam (OSTRA) Collaborative Study Radiographic damage associated with low bone mineral density and vertebral deformities in rheumatoid arthritis: the Oslo-Truro-Amsterdam (OSTRA) collaborative study. Arthritis Rheum. 2003 Apr 15;49(2):209–215. doi: 10.1002/art.10996. [DOI] [PubMed] [Google Scholar]
  24. Lundberg Ingrid E., Grundtman Cecilia, Larsson Esbjörn, Klareskog Lars. Corticosteroids--from an idea to clinical use. Best Pract Res Clin Rheumatol. 2004 Feb;18(1):7–19. doi: 10.1016/j.berh.2003.10.003. [DOI] [PubMed] [Google Scholar]
  25. Radia M., Furst D. E. Comparison of three pulse methylprednisolone regimens in the treatment of rheumatoid arthritis. J Rheumatol. 1988 Feb;15(2):242–246. [PubMed] [Google Scholar]
  26. Saag K. G., Criswell L. A., Sems K. M., Nettleman M. D., Kolluri S. Low-dose corticosteroids in rheumatoid arthritis. A meta-analysis of their moderate-term effectiveness. Arthritis Rheum. 1996 Nov;39(11):1818–1825. doi: 10.1002/art.1780391107. [DOI] [PubMed] [Google Scholar]
  27. Saag K. G., Koehnke R., Caldwell J. R., Brasington R., Burmeister L. F., Zimmerman B., Kohler J. A., Furst D. E. Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events. Am J Med. 1994 Feb;96(2):115–123. doi: 10.1016/0002-9343(94)90131-7. [DOI] [PubMed] [Google Scholar]
  28. Saag K. G. Resolved: Low-dose glucocorticoids are neither safe nor effective for the long-term treatment of rheumatoid arthritis. Arthritis Rheum. 2001 Oct;45(5):468–471. doi: 10.1002/1529-0131(200110)45:5<468::aid-art367>3.0.co;2-a. [DOI] [PubMed] [Google Scholar]
  29. Scott D. L., Dawes P. T., Fowler P. D., Shadforth M. F. Calculating radiological progression in rheumatoid arthritis. Clin Rheumatol. 1986 Dec;5(4):445–449. [PubMed] [Google Scholar]
  30. Scott D. L., Houssien D. A., Laasonen L. Proposed modification to Larsen's scoring methods for hand and wrist radiographs. Br J Rheumatol. 1995 Jan;34(1):56–56. doi: 10.1093/rheumatology/34.1.56. [DOI] [PubMed] [Google Scholar]
  31. Wolfe F., Sharp J. T. Radiographic outcome of recent-onset rheumatoid arthritis: a 19-year study of radiographic progression. Arthritis Rheum. 1998 Sep;41(9):1571–1582. doi: 10.1002/1529-0131(199809)41:9<1571::AID-ART7>3.0.CO;2-R. [DOI] [PubMed] [Google Scholar]
  32. Wong C. S., Champion G., Smith M. D., Soden M., Wetherall M., Geddes R. A., Hill W. R., Ahern M. J., Roberts-Thomson P. J. Does steroid pulsing influence the efficacy and toxicity of chrysotherapy? A double blind, placebo controlled study. Ann Rheum Dis. 1990 Jun;49(6):370–372. doi: 10.1136/ard.49.6.370. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. van Everdingen Amalia A., Jacobs Johannes W. G., Siewertsz Van Reesema Dirk R., Bijlsma Johannes W. J. Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side effects: a randomized, double-blind, placebo-controlled clinical trial. Ann Intern Med. 2002 Jan 1;136(1):1–12. doi: 10.7326/0003-4819-136-1-200201010-00006. [DOI] [PubMed] [Google Scholar]
  34. van Staa T. P., Leufkens H. G., Cooper C. Use of inhaled corticosteroids and risk of fractures. J Bone Miner Res. 2001 Mar;16(3):581–588. doi: 10.1359/jbmr.2001.16.3.581. [DOI] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES